Supplementary Information for

Theranostic supramolecular polymers formed by self-assembly of a metal-chelating prodrug

Hao Su,^{†a} Yonggang Cui,^{†b} Feihu Wang,^a Weijie Zhang,^{ac} Chunli Zhang,^b Rongfu Wang^{b*} and Honggang Cui,^{ade*}

^aDepartment of Chemical and Biomolecular Engineering, and Institute for NanoBioTechnology, The Johns Hopkins University, 3400 North Charles Street, Baltimore, Maryland 21218 United States. E-mail: hcui6@jhu.edu

^bDepartment of Nuclear Medicine, Peking University First Hospital, 8 Xishiku Dajie, Xicheng District, Beijing, 100034, China.

^cDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, 1 Jianshe Eastern Road, Zhengzhou 450052, Henan, China.

^dCenter for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, 400 North Broadway, Baltimore, Maryland 21231, United States.

^eDepartment of Oncology and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States.

[†] These authors contributed equally to this work.

Corresponding email: rongfu_wang@163.com; https://doi.org/10.1011/journal.pdf

This file includes: Figures S1 to S7



Figure S1. Synthetic protocols of CPT-etcSS-Pyr.



Figure S2. H-NMR spectrum of CPT-etcSS-Pyr.



Figure S3. Analytical RP-HPLC (A) and ESI-MS (B) spectra of CPT-etcSS-Pyr.



Figure S4. Analytical RP-HPLC (A) and ESI-MS (B) spectra of dCPT-K.



Figure S5. Analytical (A) and preparative (B) RP-HPLC of crude mixture after conjugation of DOTA with dCPT-K.



Figure S6. Analytical RP-HPLC (A) and ESI-MS (B) spectra of theranostic TT 5 (dCPT-DOTA).



Figure S7. Addition cryo-TEM (A and C) and conventional TEM (B) images of assembled TT 5.